Evidence map›Paper›PMID 38101486›Full record

ArticleInternational journal of radiation oncology, biology, physics2024

Impact of Apolipoprotein E Genotype on Neurocognitive Function in Patients With Brain Metastases: An Analysis of NRG Oncology's RTOG 0614.

Jeffrey S Wefel, Snehal Deshmukh, Paul D Brown, David R Grosshans, Erik P Sulman, Jane H Cerhan, Minesh P Mehta, Deepak Khuntia, Wenyin Shi, Mark V Mishra and 9 more

Open access · greenAbstract read
In one paragraph

Article in International journal of radiation oncology, biology, physics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Cancer treatment-related cognitive impairment.Neuro-oncology advances · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 14 institutions in 2 countries.

Jeffrey S WefelUniversity of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: jwefel@mdanderson.org.
Snehal DeshmukhNRG Oncology Statistics and Data Management Center/American College of Radiology, Philadelphia, Pennsylvania.
Paul D BrownMayo Clinic, Rochester, Minnesota.
David R GrosshansUniversity of Texas MD Anderson Cancer Center, Houston, Texas.
Erik P SulmanLaura and Isaac Perlmutter Cancer Center, New York University Langone, New York, New York.
Jane H CerhanMayo Clinic, Rochester, Minnesota.
Minesh P MehtaBaptist Hospital of Miami and Florida International University, Miami, Florida.
Deepak KhuntiaEast Bay Radiation Oncology Center, Oakland, California.
Wenyin ShiThomas Jefferson University Hospital, Philadelphia, Pennsylvania.
Mark V MishraUniversity of Maryland Medical Systems, Baltimore, Maryland.
John H SuhCleveland Clinic Foundation, Cleveland, Ohio.
Nadia N LaackMayo Clinic, Rochester, Minnesota.
Yuhchyau ChenUniversity of Rochester, Rochester, New York.
Amarinthia Amy CurtisSpartanburg Medical Center, Accruals for Upstate Carolina NCORP-Gibbs Regional Cancer Center, Spartanburg, South Carolina.
Joanna M LabaLondon Regional Cancer Program, Accruals for University of Western Ontario, London, Ontario, Canada.
Ahmed ElsayedToledo Community Hospital Oncology Program CCOP, Toledo, Ohio.
Anu ThakrarJohn H. Stroger Jr Hospital of Cook County MBCCOP, Chicago, Illinois.
Stephanie L PughNRG Oncology Statistics and Data Management Center/American College of Radiology, Philadelphia, Pennsylvania.
Deborah W BrunerEmory University, Atlanta, Georgia.
Mayo Clinic · USAmerican College of Radiology · USThe University of Texas MD Anderson Cancer Center · USCleveland Clinic · USCommunity Hospital · USEmory University · USFlorida International University · USJohn H. Stroger, Jr. Hospital of Cook County · USNYU Langone Health · USSpartanburg Regional Medical Center · USThomas Jefferson University Hospital · USUniversity of Maryland Medical System · USUniversity of Rochester · USWestern University · CA

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI James J. Dignam · 2014 to 2026
$146.4M
NRG Oncology NCORP Research Base-BIQSFPUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · 2014 to 2026
$140.5M
NRG Oncology Biospecimen BankU24CA196067 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Tanner J. Freeman, Nilsa Del Carmen Ramirez Milan · 2015 to 2026
$42.6M
Stroger Hospital of Cook County (SHCC) NCORPUG1CA190000 · NCI · HEKTOEN INSTITUTE FOR MEDICAL RESEARCH · PI Deimante Tamkus · 2014 to 2026
$11.1M
NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180868NCI NIH HHS U24 CA196067NCI NIH HHS UG1 CA189867NCI NIH HHS UG1 CA190000
6 · The paper itself

Abstract

purposeWhole-brain radiation therapy (WBRT) is a common treatment for brain metastases and is frequently associated with decline in neurocognitive functioning (NCF). The e4 allele of the apolipoprotein E (APOE) gene is associated with increased risk of Alzheimer disease and NCF decline associated with a variety of neurologic diseases and insults. APOE carrier status has not been evaluated as a risk factor for onset time or extent of NCF impairment in patients with brain metastases treated with WBRT. METHODS AND MATERIALS: NRG/Radiation Therapy Oncology Group 0614 treated adult patients with brain metastases with 37.5 Gy of WBRT (+/- memantine), performed longitudinal NCF testing, and included an optional blood draw for APOE analysis. NCF test results were compared at baseline and over time with mixed-effects models. A cause-specific Cox model for time to NCF failure was performed to assess the effects of treatment arm and APOE carrier status.

resultsAPOE results were available for 45% of patients (n = 227/508). NCF did not differ by APOE e4 carrier status at baseline. Mixed-effects modeling showed that APOE e4 carriers had worse memory after WBRT compared with APOE e4 noncarriers (Hopkins Verbal Learning Test-Revised total recall [least square mean difference, 0.63; P = .0074], delayed recognition [least square mean difference, 0.75; P = .023]). However, APOE e4 carrier status was not associated with time to NCF failure (hazard ratio, 0.86; 95% CI, 0.60-1.23; P = .40). Memantine delayed the time to NCF failure, regardless of carrier status (hazard ratio, 0.72; 95% CI, 0.52-1.01; P = .054).

conclusionsAPOE e4 carriers with brain metastases exhibited greater decline in learning and memory, executive function, and the Clinical Trial Battery Composite score after treatment with WBRT (+/- memantine), without acceleration of onset of difference in time to NCF failure.

Indexed as

Brain NeoplasmsMemantineAdultAgedApolipoprotein E4Apolipoproteins ECognitionCranial IrradiationFemaleGenotypeHeterozygoteHumansMaleMiddle AgedProportional Hazards ModelsApoE protein, humanApolipoprotein E4Apolipoproteins EMemantine

Identifiers

PMID38101486
PMCPMC11162903
OpenAlexW4389687916

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.